Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
77M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
9.39M
-
Shares change
-
+573K
-
Total reported value, excl. options
-
$7.51M
-
Value change
-
+$449K
-
Number of buys
-
12
-
Number of sells
-
-12
-
Price
-
$0.80
Significant Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q2 2025
52 filings reported holding CLSD - Clearside Biomedical, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.39M shares
of 77M outstanding shares and own 12.19% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.36M shares), Carmignac Gestion (1.51M shares), GEODE CAPITAL MANAGEMENT, LLC (790K shares), BlackRock, Inc. (625K shares), GSA CAPITAL PARTNERS LLP (534K shares), RENAISSANCE TECHNOLOGIES LLC (497K shares), FIRST MANHATTAN CO. LLC. (343K shares), STATE STREET CORP (265K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (205K shares), and NORTHERN TRUST CORP (165K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.